368866-30-2 Usage
Uses
Used in Organic Synthesis:
4-Piperidinecarboxylicacid,4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-(phenylmethyl)-(9CI) is used as a building block in organic synthesis for the creation of complex molecular structures. Its unique functional groups and structural features enable the formation of diverse chemical entities with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Piperidinecarboxylicacid,4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-(phenylmethyl)-(9CI) serves as a key component in the synthesis of peptide and protein-based drugs. Its presence in these molecules can contribute to their biological activity and therapeutic potential.
Used as a Protecting Group in Peptide Synthesis:
4-Piperidinecarboxylicacid,4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-(phenylmethyl)-(9CI) is utilized as a protecting group for amino acids during peptide synthesis. The Fmoc group provides stability to the amino group, allowing for selective deprotection during the assembly of peptide chains. This selective protection and deprotection process is crucial for the successful synthesis of peptides with specific sequences and functions.
Used in Pharmaceutical Industry:
4-Piperidinecarboxylicacid,4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-(phenylmethyl)-(9CI) is used as a key intermediate in the development of pharmaceutical compounds. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacokinetic properties, leading to improved therapeutic outcomes for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 368866-30-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,8,8,6 and 6 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 368866-30:
(8*3)+(7*6)+(6*8)+(5*8)+(4*6)+(3*6)+(2*3)+(1*0)=202
202 % 10 = 2
So 368866-30-2 is a valid CAS Registry Number.
368866-30-2Relevant academic research and scientific papers
Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor
Jin, Feng,Gao, Dan,Wu, Qin,Liu, Feng,Chen, Yuzong,Tan, Chunyan,Jiang, Yuyang
, p. 5694 - 5706 (2013/09/12)
VEGFR, ERK and Abl had been respectively identified as good drug targets, and their crosstalk also had been well elaborated. Multitarget drugs were more advantageous for cancer treatment, however, no inhibitors simultaneously acting on the three proteins were developed due to their structural diversities. Herein, N-(4-((2-(2-(naphthaen-1-yl)acetamido)ethyl)carbamoyl)piperidin-4-yl)-6- (trifluoromethyl)nicotinamide (NEPT, 6a) was discovered as an active scaffold against VEGFR-2, ERK-2 and Abl-1 kinases through the combination of support vector machine, similarity searching and molecular docking. NEPT and its derivatives were synthesized by convenient routine, their in vitro anti-proliferative abilities against human liver cancer cell line HepG2 were preliminarily evaluated. A representative compound 6b showed an IC50 value of 11.3 μM and induced significant HepG2 cells apoptosis. Besides, these compounds displayed better anti-proliferative abilities against K562 cells (a cell line with typical hyperactivity of the above multikinases), for example compound 6b exhibited an IC50 value of 4.5 μM. Based on hepatotoxicity case reports of Abl inhibitors, cytotoxicity of synthetic compounds against normal liver cell lines (QSG7701 and HL7702) was studied, 6b had a similar toxic effect with positive control imatinib, and most compounds showed less than 35% inhibition activities at 100 μM. Molecular docking study disclosed interactions of 6b with VEGFR-2, ERK-2 and Abl-1 kinases, respectively. Our data suggested the biological activities of 6b may derived from collaborative effects of VEGFR-2, ERK-2 and Abl-1 inhibition.
